Here is what it says,
"Besides its well-recognized predictive role in GBM patients undergoing standard
chemoradiation with TMZ, MGMT promoter methylation is emerging as a factor potentially associated with improved outcomes in patients receiving different immunotherapeutic strategies. Again in the Checkmate 143 trial, MGMT methylated patients with no
baseline corticosteroid use had a trend toward improved OS with nivolumab (17.0
months) vs. bevacizumab (10.1 months) [31]. Moreover, preliminary data from a phase 3
randomized, double-blinded, placebo-controlled clinical trial of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) for newly diagnosed GBM showed that the
median OS was 34.7 months (95% CI 27.0–40.7) and 19.8 months (95% CI 17.9–21.7), in
patients with methylated and unmethylated MGMT, respectively [60]. A possible explanation for these findings is that MGMT methylated tumors exhibit four more times the
number of somatic mutations than MGMT-unmethylated GBM, making these tumors
more immunogenic and more susceptible to the action of different immunotherapeutic
approaches [61]"
Which gets its info from:
Liau, L.M.; Ashkan, K.; Tran, D.D.; Campian, J.L.; Trusheim, J.E.; Cobbs, C.S.; Heth, J.A.; Salacz, M.; Taylor, S.; D’Andre, S.D.;
et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed
glioblastoma. J. Transl. Med. 2018, 16, 142, doi:10.1186/s12967-018-1507-6.
So their 2018 paper, no new news from this, just a reference to the study showing the difference between Methylated vs Unmethylated it seems like.
News 
Market Data 
Discover 
